Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
A new cancer biotechnology company, TCRyption Inc., has been launched based on innovative findings from the Princess Margaret Cancer Centre (PM).
TCRyption Inc. emerges from the groundbreaking T-cell immunotherapy technologies created by PM Senior Scientist Dr.
Naoto Hirano. The company was founded by Dr. Hirano along with pioneers of the T-cell and cancer fields, Drs.
Tak Mak and
The technology developed by Dr. Hirano belongs to a branch of cancer immunotherapy known as a T-cell receptor (TCR)-based adoptive cellular therapy and helps to stimulate the body's own immune response to destroy cancer cells.
Unfortunately, the effectiveness of this therapy is dependent on the HLA type of the patient (ie, the presence of certain immune molecules, of which there are many types that vary between patients). Due to this, current therapies are generally effective for only a small patient group.
Dr. Hirano has overcome this problem through the development of a methodology that can generate an effective personalized therapeutic regimen for any patient's HLA type regardless of its frequency – an innovation that will greatly expand treatment options and the groups of patients that can benefit from them.
"We are very pleased to announce the launch of TCRyption; such innovative biotech partners embrace the power of immunity to fight cancer but also recognize that many current TCR-based applications will benefit only some patients,” says Dr. Hirano. "Our methodology at TCRyption allows us to bolster precision medicine for all patients and is an important part of helping us move forward together in our common goal to conquer cancer."
With early support from the Princess Margaret Cancer Centre Innovation Acceleration Fund for developing the technology, company creation activities were led by UHN’s
Technology Development & Commercialization team (TDC) and
TIO Bioventures with an initial $10 million in seed financing to advance the innovation so that it can help patients.
"We are thrilled to have TCRyption launched with the core facilities located right here in Toronto with some of the biggest names and pioneers in cancer immunology as part of the team," says Mark Taylor, Director of UHN's TDC.